Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Regadenoson; Optison · 1 trial · 2 indications
Measurements will be analyzed to identify a coronary stenosis \>50% in diameter by quantitative cardiac angiography.
| Arm | Type | Description |
|---|---|---|
| Regadenoson; Optison | EXPERIMENTAL | Use of Regadenoson as the chemical stress agent using Optison as a contrast agent during stress echocardiography. |
| Name | Type | Description |
|---|---|---|
| Regadenoson; Optison | DRUG | A one-time intravenous bolus of Regadenoson 400 mcg; continuous intravenous infusion of Optison of 2-4 mL/minute. |
Inclusion Criteria: * Male or female. Age ≥ 30 years. * Resting Left Ventricular Ejection Fraction \> 40% using Simpson's biplane measurement. * Scheduled for coronary angiography within 30 days of the Regadenoson stress test. * Negative urine pregnancy test within 2 hours of ultrasound contrast ad...
Regadenoson Optison is used for coronary artery disease and myocardial perfusion abnormalities. It is a small molecule cardiovascular therapy being developed by GE HealthCare Technologies Inc. (GEHC). The drug is currently in Phase 3 clinical development, with one completed trial involving 50 participants in the United States.
Regadenoson Optison is a small molecule cardiovascular therapy. It is being studied for use in coronary artery disease and myocardial perfusion abnormalities. The drug is in Phase 3 clinical development, with a completed trial (NCT01489176) that enrolled 50 patients in the United States.
GE HealthCare Technologies Inc. (GEHC) is developing Regadenoson Optison. The drug is a small molecule cardiovascular therapy in Phase 3 clinical development for coronary artery disease and myocardial perfusion abnormalities. One clinical trial has been completed with 50 participants.
Regadenoson Optison is in Phase 3 clinical development. It is an investigational small molecule therapy for coronary artery disease and myocardial perfusion abnormalities. The drug has completed one Phase 3 trial (NCT01489176) with 50 participants in the United States, and it is not yet approved.
Regadenoson Optison has one completed clinical trial, NCT01489176, titled "Regadenoson Real Time Perfusion Imaging Trial-Optison." This Phase 3 study enrolled 50 participants with coronary artery disease and myocardial perfusion abnormalities in the United States. The trial was uncontrolled and not randomized or double-blinded.
Regadenoson Optison is a combination therapy that includes Regadenoson and Optison. It is being developed by GE HealthCare Technologies Inc. (GEHC) for coronary artery disease and myocardial perfusion abnormalities. The drug is in Phase 3 clinical development, with one completed trial involving 50 patients.